Indinavir overdosage

Jump to navigation Jump to search
Indinavir
CRIXIVAN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overdosage

There have been more than 60 reports of acute or chronic human overdosage (up to 23 times the recommended total daily dose of 2400 mg) with CRIXIVAN. The most commonly reported symptoms were renal (e.g., nephrolithiasis/urolithiasis, flank pain, hematuria) and gastrointestinal (e.g., nausea, vomiting, diarrhea).

It is not known whether CRIXIVAN is dialyzable by peritoneal or hemodialysis.[1]

References

  1. "CRIXIVAN (INDINAVIR SULFATE) CAPSULE [MERCK SHARP & DOHME CORP.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.